Study summary · research use only
A GH Secretagogue Receptor Agonist (LUM-201) Elicits Greater GH Responses than Standard GH Secretagogues in Subjects of a Pediatric GH Deficiency Trial
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this human trial involving 68 pediatric subjects with growth hormone deficiency, researchers compared the growth hormone (GH) response to a single dose of LUM-201 (ibutamoren, formerly MK-0677) with responses to standard GH secretagogues used diagnostically (arginine, glucagon, clonidine, L-dopa, and insulin-induced hypoglycemia). LUM-201 was associated with greater GH responses than the standard diagnostic tests, with a median (interquartile range) of 15.0 ng/mL (3.5, 49) versus 5.5 ng/mL (1.8, 7.6). The difference was reported as greatest in subjects with higher baseline IGF-I concentrations and higher GH responses to standard stimuli. The authors describe LUM-201 as a potential orally administered alternative to injectable growth hormone in a subset of patients with adequate responses to an acute LUM-201 dose.
Abstract
LUM-201 (ibutamoren, formerly MK-0677) is an orally administered GH secretagogue receptor agonist under development for treatment of pediatric growth hormone deficiency (PGHD). The GH response to a single dose of LUM-201 and to other GH secretagogues used for diagnosis of PGHD were compared in 68 pediatric subjects participating in a trial for growth hormone deficiency. LUM-201 elicited greater GH responses than observed in GHD diagnostic tests with arginine, glucagon, clonidine, L-dopa, and insulin-induced hypoglycemia [median and interquartile ranges 15.0 ng/mL (3.5, 49) vs. 5.5 ng/mL (1.8, 7.6) (p < 0.0001)]. The difference between responses was greatest in subjects with higher baseline IGF-I concentrations and higher GH responses to standard GH stimuli. LUM-201 elicits greater GH responses than standard stimuli in subjects with higher peak GH in response to conventional testing and is potentially an orally administered treatment alternative to injectable rhGH in a subset of patients with adequate responses to an acute dose of LUM-201.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.